Home Administration of Bortezomib: Making a Difference to Myeloma Patients' Lives

European Journal of Oncology Nursing - United States
doi 10.1016/j.ejon.2009.09.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Intravenous (IV) Bortezomib Infusion After Non-Response to Subcutaneous Bortezomib Administration Can Induce Transitory Responses in Multiple Myeloma Patients: Are Some Patients More Sensitive to IV Bortezomib?

British Journal of Haematology
Hematology
2016English

Productivity Costs Related to Bortezomib and Carfilzomib Administration for Multiple Myeloma in Finland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Cutaneous Myeloma and Bortezomib

Annals of Hematology
MedicineHematology
2009English

Blood Distribution of Bortezomib and Its Kinetics in Multiple Myeloma Patients

Clinical Biochemistry
MedicineClinical Biochemistry
2014English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Making a Difference

British Journal of Mental Health Nursing
2012English

Making a Difference

Nature
Multidisciplinary
2004English

Making a Difference

Relations industrielles
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy